5-氮杂-2'-脱氧胞苷对HepG2细胞RUNX3基因表达及细胞增殖的影响

目的探讨人肝癌细胞系HepG2经5-氮杂-2’-脱氧胞苷(5-Aza-2-’deoxycytid ine,5-Aza-CdR)处理后诱导高甲基化失活的RUNX3基因重新表达的可能性及对细胞生长的影响,寻找抗癌治疗的新靶点。方法RT-PCR检测抑癌基因RUNX3 mRNA的表达;MTT、集落形成实验观察细胞的生长活性;流式细胞术和透射电镜分析细胞周期及细胞凋亡的变化。结果肝癌细胞经不同浓度之5-Aza-CdR处理后,原无RUNX3 mRNA表达的细胞均检出基因重新表达,细胞生长速度出现不同程度减慢及细胞克隆形成率显著降低(P<0.01)。用药后肝癌细胞发生明显的S期阻滞,电镜显示肝癌细胞形态学改变。结论去甲基化制剂5-Aza-CdR能有效地激活肝癌细胞系HepG2因高甲基化所致RUNX3基因沉默的再转录,诱导该基因的表达,从而抑制肿瘤细胞生长。     

Therapeutic potential of chlorotoxin-like neurotoxin from the Chinese scorpion for human gliomas

Chlorotoxin, one of the key toxins in scorpion Leiurus quinquestriatus venom, has been shown to bind specifically to glioma cell surface as a specific chloride channel blocker. In this study, a purified, recombinant chlorotoxin-like peptide from the scorpion Buthus martensii Karsch (named rBmK CTa) was characterized by in vivo and in vitro studies. The results from cell proliferation assay with human glioma (SHG-44) cells showed that rBmK CTa inhibits the growth of glioma cells in a dose-dependent manner, with an IC₅₀ value of approximately 0.28 μM. Under the same conditions, the IC₅₀ value for normal astrocytes increased to 8 μM. This clearly indicated that rBmK CTa had specific toxicity against glioma cells but not astrocytes. Results from whole-cell patch-clamp recording showed that chloride current in SHG-44 was inhibited by rBmK CTa in a voltage-dependent manner and percent inhibitions for the blocking action of rBmK CTa (0.07 and 0.14 μM) on I_Cl was 17.64 ± 3.06% and 55.86 ± 2.83%, respectively. Histological analysis of rBmK CTa treated mice showed that brain, leg muscle and cardiac muscle were the target organs of this toxin. These results suggest that rBmK CTa may have potential therapeutic application in clinical treatment of human glioma. It represents an approach for developing a novel therapeutic agent.     

Changes in agent variability and time course of disease incidence during a year (as exemplified by dysentery)

The vulnerability of epidemic process during the period of minimum annual incidence of the disease is validated. Biological properties of Shigella sonnei are studied and their variability examined using the index for evaluation of the mean number of variations for a sign. Minimum agent heterogeneity coincides with minimum incidence of disease and maximum heterogeneity with its seasonal rises.     

宫颈癌细胞产生的免疫抑制因子对IL－2作用的影响

人宫颈癌细胞产生的免疫抑制因子（ＴＤＳＦ）作用于人外周血单个核细胞（ＰＢＭＣ）６ｈ，即可抑制白细胞介素２（ＩＬ－２）产生，与对照组相比，Ｐ＜０．０１。当ＴＤＳＦ存在时，经ＰＨＡ－Ｐ驯化的ＰＢＭＣ效应细胞对外源性ＩＬ－２反应显著减弱，表明ＴＤＳＦ能抑制ＩＬ－２的作用。ＰＨＡ－Ｐ刺激ＰＢＭＣ增殖，但ＴＤＳＦ使其增殖抑制。表明ＴＤＳＦ能抑制ＩＬ－２产生及其作用；抗癌药对ＴＤＳＦ的分泌有部分阻抑作用。     

Pharmacological and clinical effects of buspirone

Clinical trials have demonstrated that buspirone (BuSpar) is effective in the treatment of anxiety with efficacy and dosage comparable to diazepam or chlorazepate. Buspirone has a unique structure and a pharmacologic profile which distinguishes it from the benzodiazepines. Because it lacks the anticonvulsant, sedative, and muscle-relaxant properties associated with other anxiolytics, buspirone has been termed "anxioselective." Animal studies suggest that it lacks potential for abuse, and this finding is supported by clinical investigations. Further preclinical work supports the contention that buspirone lacks liability to produce physical dependence or to significantly interact with central nervous system depressants such as ethanol. Moreover, biochemical investigations have not identified any direct interaction of buspirone with the benzodiazepine-gamma-aminobutyric acid-chloride ionophore complex. Pharmacologic studies on the molecular level indicate that buspirone interacts with dopamine and serotonin receptors. Recent behavioral, electrophysiological, and biochemical studies have clearly demonstrated that early hypotheses that buspirone might be considered a neuroleptic are no longer tenable. Recent evidence indicates that other neurotransmitter systems (serotonin, norepinephrine, acetylcholine) mediate buspirone's effects. It is hoped that future studies can define the mechanism by which buspirone alleviates the clinical manifestations of anxiety.     

Handling of biological samples in the determination of the anti-neoplastic drug mitomycin C

A study to ascertain suitable conditions for handling biological samples from patients, treated with the antibiotic mitomycin C (MMC), with the objective of improving the accuracy and reliability of the determination is described. Situations frequently occurring in medical practice are simulated to optimize procedures for reliable and reproducible sampling, sample treatment and determination of MMC. Continuation of drug partitioning in whole blood after sampling can be prevented by immediate cooling in ice before the separation of plasma from cells. The adjustment of the pH of urine samples is shown to be particularly important since a low urinary pH causes decomposition of MMC; moreover, it may decrease extraction recovery. Furthermore, long-term exposure of samples to daylight induces drug decomposition. Frozen storage of plasma and urine samples for periods greater than 3 weeks is to be avoided as this results in a considerable drop in MMC concentration. Repeated cycles of freezing and thawing are shown to have no effect upon the analytical results (6 cycles tested). The analysis of extracts of biological samples may take place up to at least 24 h after their preparation without measurable loss of analyte.     

全国细菌耐药监测网2014—2019年尿标本细菌耐药监测报告

目的探讨全国尿标本分离细菌菌种分布及耐药变迁。方法按照全国细菌耐药监测网(CARSS)技术方案,应用WHONET5.6软件对2014—2019年所有CARSS成员单位上报的尿标本分离细菌及药敏结果数据进行分析。结果男性患者尿标本分离细菌居前5位者分别为大肠埃希菌(33.1%~34.6%)、粪肠球菌(9.2%~10.2%)、肺炎克雷伯菌(9.0%~9.4%)、屎肠球菌(7.8%~10.2%)和铜绿假单胞菌(5.6%~6.9%),女性患者尿标本分离细菌居前5位者分别为大肠埃希菌(57.0%~57.4%)、肺炎克雷伯菌(7.5%~8.3%)、屎肠球菌(6.8%~8.7%)、粪肠球菌(5.5%~6.0%)和奇异变形杆菌(3.3%~3.5%)。男性和女性患者尿标本分离粪肠球菌对氨苄西林和呋喃妥因耐药率分别<12%和7%,对万古霉素耐药率<3%;屎肠球菌对氨苄西林、左氧氟沙星耐药率均为90%左右,对万古霉素耐药率<4%。大肠埃希菌对头孢曲松耐药率>47%,对头孢哌酮/舒巴坦、哌拉西林/他唑巴坦、呋喃妥因耐药率≤8%,对于β-内酰胺类耐药率男性比女性高,其中头孢曲松的耐药率高12个百分点左右。男性患者分离肺炎克雷伯菌对头孢曲松耐药率为58%左右,女性患者耐药率为45%左右。男性和女性患者尿标本分离铜绿假单胞菌对头孢哌酮/舒巴坦和哌拉西林/他唑巴坦的耐药率均<14%,对碳青霉烯类耐药率为15%左右。鲍曼不动杆菌对头孢哌酮/舒巴坦和米诺环素耐药率分别<27%和22%,对碳青霉烯类耐药率,男性为31.7%~47.7%,女性为26.5%~41.2%。结论尿标本分离细菌在不同性别构成上有所不同,且部分肠杆菌目细菌耐药率不同性别间也有一定差异,不同年度间部分细菌的耐药率也有一定变化。尿标本分离细菌的耐药监测,可为尿路感染抗菌药物合理应用提供参考数据。     

复方磺胺嘧啶锌涂膜剂治疗烧伤的疗效观察

目的 观察复方磺胺嘧啶锌涂膜剂治疗浅Ⅱ度、深Ⅱ度 烧伤创面、残余创面抗感染和促进创面愈合的作用。方法 治疗组清 创 后应用复方磺胺嘧啶锌涂膜剂涂于创面的表面,对照组应用1%磺胺嘧啶银霜覆盖创面,共治 疗119例烧伤患者(即222个创面),包括浅Ⅱ度烧伤、深Ⅱ度烧伤、残余小创面及供皮区创面 ,并观察创面完全愈合时间、创面表面细菌培养用药前与用药中的情况以及复方磺胺嘧啶锌 涂膜剂对全身情况的影响。结果 浅Ⅱ度烧伤创面治疗组(10.25±1 .6 9)天完全愈合,对照组(13.15±2.03)天愈合;深Ⅱ度创面治疗组(18.10±2.72)天愈合 ,对照组(21.2±3.64)天愈合,治疗组明显优于对照组(P＜0.05);治疗组用药前细 菌培养阳性率是38.8%,治疗中降至9.0%;对照组用药前细菌培养阳性率为32.7%,治疗 中降至25.4%;两组间比较具有显著性差异(P＜0.05);患者未出现疼痛、过敏反应 和其它不良反应。结论 复方磺胺嘧啶锌涂膜剂治疗烧伤创面可促进上 皮 化、加速创面愈合、有效地防治创面感染,该药应用简便、适用于社区、基层常见的中、小 面积浅度烧伤治疗。     

高渗和低渗造影剂对大白鼠肾毒性的实验研究

目的 :研究高、低渗造影剂对甘油致肾损害大鼠和正常大鼠的肾毒性 ,观察山莨菪碱预防肾小管损害的作用。方法 :用 2 5 %甘油按 1ml/ 10 0 g制肾损害大鼠模型 ,然后从静脉注射高渗造影剂 (76 %复方泛影葡胺 ,1ml/ 10 0 g)或优维显 (1m l/ 10 0 g) ,2 4h后各组随机处死 10只大鼠 ,肾脏用 10 %福尔马林固定后做病理检查。结果 :在肾功能损害组 ,给高渗造影剂后 ,可使肾小管管型数和肾小管坏死数明显高于低渗造影剂组和甘油对照组 (P<0 .0 1) ,山莨菪碱可明显减轻肾小管损害 (P<0 .0 5 )。正常肾功能组高、低渗造影剂组之间肾小管损害无显著性差异。结论 :肾功能损害时用低渗造影剂对肾毒性较小 ,山莨菪碱对复方泛影葡胺的肾毒性有一定的预防作用。     

药用辅料在制剂中的应用概述

药用辅料是药物制剂的基础材料的重要的组成部分,在制剂型和生产中起着关键作用,它不仅赋予药物一定剂型,并且与提高药物的疗效,降低毒副作用有很大的关系,因此,研究开发,合理应用辅仅可提高药物制剂质量和生产技术水平,而且可取得较大的社会及经济效益。